Edwards Lifesciences (NYSE: EW) executive logs routine tax-withholding share disposition

Rhea-AI Filing Summary

Edwards Lifesciences Corp executive Daniel J. Lippis reported a small tax-related share disposition. On May 11, 2026, 362 shares of common stock were disposed of at $79.96 per share to cover tax obligations. After this non-market transaction, he directly holds about 40,410.91 shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Lippis Daniel J.

Role CVP, TAVR

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	362	$79.96	$29K

Holdings After Transaction: Common Stock — 40,410.91 shares (Direct, null)

Footnotes (1)

Key Figures

Tax-withholding shares: 362 shares Tax-withholding price: $79.96 per share Shares held after transaction: 40,410.9103 shares

3 metrics

Tax-withholding shares 362 shares Common Stock disposed for tax withholding on May 11, 2026

Tax-withholding price $79.96 per share Value used for 362-share tax-withholding disposition

Shares held after transaction 40,410.9103 shares Direct holdings of Daniel J. Lippis after Form 4 event

Key Terms

tax-withholding disposition, Common Stock, transaction code F

3 terms

tax-withholding disposition financial

"transaction_action: "tax-withholding disposition""

A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.

Common Stock financial

"security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

transaction code F financial

"transaction_code_description: "Payment of exercise price or tax liability by delivering securities""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lippis Daniel J.

(Last) (First) (Middle)

ONE EDWARDS WAY

(Street)

IRVINE CALIFORNIA 92614

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Edwards Lifesciences Corp [ EW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CVP, TAVR

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/11/2026		F		362	D	$79.96	40,410.9103	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

	Linda J. Park, Attorney-in-Fact	05/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Edwards Lifesciences (EW) report for Daniel J. Lippis?

Edwards Lifesciences reported a small tax-withholding disposition by executive Daniel J. Lippis. He disposed of 362 common shares at $79.96 per share, used to satisfy tax obligations rather than as an open-market sale.

Was the Edwards Lifesciences (EW) Form 4 transaction a market sale?

No, the Form 4 shows a tax-withholding disposition, not an open-market sale. Code F means shares are surrendered to cover tax liabilities arising from equity compensation, so it does not reflect an active decision to sell shares in the market.

How many Edwards Lifesciences (EW) shares does Daniel J. Lippis hold after the Form 4 transaction?

After the reported transaction, Daniel J. Lippis directly holds about 40,410.91 Edwards Lifesciences common shares. The filing shows this post-transaction balance following the tax-withholding disposition of 362 shares on May 11, 2026.

What does transaction code F mean in the Edwards Lifesciences (EW) Form 4?

Transaction code F on the Form 4 indicates a payment of exercise price or tax liability by delivering shares. In this case, 362 shares were surrendered to cover taxes related to equity compensation, rather than being sold on the open market.

Does the Edwards Lifesciences (EW) Form 4 show any insider buying or selling in the market?

The Form 4 does not show any open-market buying or selling. It reports only a tax-withholding disposition of 362 shares, classified as code F, which is a routine administrative event tied to equity compensation taxes.